The quantitation of HCV RNA in whole blood samples obtained from individual subjects at specific time-points during the course of treatment of Hepatitis C,
Role: Investigator,
Discovery Life Sciences, Inc.,
(01/2021 - 01/2022)
Status: Completed
NeuWave Medical Inc., NEU-2017-04: A multicenter observational registry to develop ablation parameter guidance for microwave liver ablation of soft tissue lesions,
Role: Investigator,
Neuwave Medical, Inc.,
(12/2019)
Status: Approved
A randomized, global, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-daily oral avatrombopag for the treatment of adults with thrombocytopenia associated with liver disease prior to an elective procedure (Eisai, May 2015),
Role: PI,
Eisai Medical Research, Inc.,
(08/2016 - 08/2017)
Status: Completed
A multicenter, double-blind, placebo controlled study to evaluate the safety, tolerability and efficacy of IDN-6556 in subjects with liver cirrhosis (conatus cirrhosis 9Jun14),
Role: Investigator,
Conatus Pharmaceuticals Inc.,
(07/2015 - 07/2016)
Status: Completed
Internal
Functional assessment in liver transplantation (FrAILT) study,
Role: Investigator,
LLU Dept. of Medicine,
(03/2023 - 03/2024)
Status: Completed
Pilot investigation using HCV positive liver grafts in HCV negative or previously successfully treated recipients,
Role: Investigator,
LLU Dept. of Medicine,
(02/2022 - 02/2023)
Status: Completed
Randomized controlled trial of transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma,
Role: Investigator,
LLU Dept. of Surgery,
(07/2020 - 07/2021)
Status: Completed
Non-Profit Organization
Cirrhosis quality collaborative,
Role: Investigator,
American Association for the Study of Liver Diseases,
(04/2019)
Status: Completed
Introducing Palliative Care (PC) within the treatment of End Stage Liver Disease (ESLD): A cluster randomized controlled trial,
Role: Investigator,
Albert Einstein Healthcare Network,
(12/2024 - 12/2025)
Status: Approved